Dr Anna Sureda, President of the European Society for Blood and Marrow Transplantation (EBMT), summarizes the main take-home messages from her educational session on the latest improvements in autologous stem cell transplantation for patients with Hodgkin lymphoma. These include the introduction of new drugs in the salvage setting such as checkpoint inhibitors, improvements to long-term outcomes for patients and a hope that in the future some patients might be spared transplant due to the introduction of new practice-changing therapies.
Disclosures: Anna Sureda has received honoraria from Alexion, Amgen, BMS/Celgene, Gilead Kite, Janssen, MSD, Novartis, Roche, Sanofi and Takeda, and consultancy fees from BMS/Celgene, Gilead, Janssen, Novartis, Sanofi and Takeda. She is on the speaker’s bureau for and has received research support from Takeda. Non-profit organizations roles include Presidency of the EBMT and presidency of the GETH-TC.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
